NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD TARRYTOWN, N.Y. and PARIS, May 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: ...

Late-Breaking Results From the Phase 2a COURSE Trial Illustrate Tezspire's Impact on COPD Exacerbations in Patients With a Broad Range of Eosinophil Levels THOUSAND OAKS, Calif., May 19, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood eosinophil counts (BEC) irrespective of emphysema, ...

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When:          May 17–22, 2024Where:         San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101                       Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101Research:     26 ResMed-supported abstracts will be presented at ATS. Full list below. Highlights:Innovation Hub:     Healthcare of Today, Looking Towards Tomorrow: Digital Innovations and Patient CentricityBooth #1442:            Featuring ResMed’s late ...

Appendix 99.1 ATS Reports Fourth Quarter and Annual 2024 Results 05/16/2024 Cambridge, ON / BUSINESS WIRE / ATS Corporation (TSX and NYSE: ATS) ("ATS" or the "Company") today reported its financial results for the three and twelve months ended March 31, 2024. All references to "$" or "dollars" in this news release are to Canadian dollars unless otherwise indicated. Fourth quarter highlights: • Revenues increased 8.3% year over year to $791.5 million. • Net Income was $48.5 million compared to $29.6 million ...

ATS Corporation (NYSE:ATS) Q4 2024 Earnings Conference Call May 16, 2024 8:30 AM ET Company Participants David Galison - Head of Investor Relations Andrew Hider - Chief Executive Officer Ryan McLeod - Chief Financial Officer Conference Call Participants David Ocampo - Cormark Securities Michael Doumet - Scotiabank Joe Ritchie - Goldman Sachs Michael Glen - Raymond James Justin Keywood - Stifel Patrick Baumann - JPMorgan Maxim Sytchev - National Bank Financial Cherilyn Radbourne - TD Securities Operator Welc ...

ATS (ATS) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.54 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 17.07%. A quarter ago, it was expected that this automation services provider would post earnings of $0.48 per share when it actually produced earnings of $0.48, delivering no surprise.Over the last four quarters, the company h ...

THOUSAND OAKS, Calif., May 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:00 p.m. PT on Monday, May 20, 2024 following the presentation of new data from TEZSPIRE® in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS) International Conference on May 19 and 20, 2024. The presentation will also include an overview of additional programs from Amgen's innovative inflammation portfolio. Jay Bradner, executive vice presiden ...

CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Raymond James 45th Annual Institutional Investors Conference in Orlando, FL on March 6, 2024. ATS is scheduled to host a fireside chat at the event at 11:00 a.m. (ET). A webcast link of the live event will be available on the Investor Relations site at https://investors.atsautomation.c ...

CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Barclays Industrials Select Conference in Miami, FL on February 22, 2024. Management will host institutional investor meetings at the Conference, which can be arranged by contacting your Barclays representative or dgalison@atsautomation.com. About ATS Corporation ATS Corporation is a ...

CAMBRIDGE, Ontario--(BUSINESS WIRE)--ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) today announced that Andrew Hider, Chief Executive Officer and Ryan McLeod, Chief Financial Officer will participate in the Citi Global Industrial Tech and Mobility Conference in Miami, FL on February 21, 2024. ATS is scheduled to host a fireside chat at the event at 10:30 a.m. (ET). A webcast link of the live event will be available on the Investor Relations site at https://investors.atsautomation.com/ in ...